{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:44:22Z","timestamp":1792100662325,"version":"4.4.0"},"reference-count":157,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T00:00:00Z","timestamp":1704153600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82102938"],"award-info":[{"award-number":["82102938"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82202429"],"award-info":[{"award-number":["82202429"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LBY23H080001"],"award-info":[{"award-number":["LBY23H080001"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LBY23H080004"],"award-info":[{"award-number":["LBY23H080004"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LBY23H080005"],"award-info":[{"award-number":["LBY23H080005"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017594","name":"Medical Science and Technology Project of Zhejiang Province","doi-asserted-by":"publisher","award":["2023KY385"],"award-info":[{"award-number":["2023KY385"]}],"id":[{"id":"10.13039\/501100017594","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017594","name":"Medical Science and Technology Project of Zhejiang Province","doi-asserted-by":"publisher","award":["2023KY550"],"award-info":[{"award-number":["2023KY550"]}],"id":[{"id":"10.13039\/501100017594","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017594","name":"Medical Science and Technology Project of Zhejiang Province","doi-asserted-by":"publisher","award":["2023RC004"],"award-info":[{"award-number":["2023RC004"]}],"id":[{"id":"10.13039\/501100017594","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017594","name":"Medical Science and Technology Project of Zhejiang Province","doi-asserted-by":"publisher","award":["2023RC228"],"award-info":[{"award-number":["2023RC228"]}],"id":[{"id":"10.13039\/501100017594","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017594","name":"Medical Science and Technology Project of Zhejiang Province","doi-asserted-by":"publisher","award":["2024KY725"],"award-info":[{"award-number":["2024KY725"]}],"id":[{"id":"10.13039\/501100017594","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017594","name":"Medical Science and Technology Project of Zhejiang Province","doi-asserted-by":"publisher","award":["2024XY184"],"award-info":[{"award-number":["2024XY184"]}],"id":[{"id":"10.13039\/501100017594","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.biopha.2024.116132","type":"journal-article","created":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T14:06:29Z","timestamp":1704809189000},"page":"116132","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"special_numbering":"C","title":["Immunotherapies of acute myeloid leukemia: Rationale, clinical evidence and perspective"],"prefix":"10.1016","volume":"171","author":[{"given":"Yunyi","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanchun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiangan","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinhao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weidong","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7519-8531","authenticated-orcid":false,"given":"Jing","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gongqiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.biopha.2024.116132_bib1","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute Myeloid Leukemia","volume":"373","author":"D\u00f6hner","year":"2015","journal-title":"N. Engl. J. Med"},{"issue":"4","key":"10.1016\/j.biopha.2024.116132_bib2","article-title":"What is the role of the bone marrow microenvironment in AML?","volume":"34","author":"Mulherkar","year":"2021","journal-title":"Best. Pr. Res Clin. Haematol."},{"issue":"9","key":"10.1016\/j.biopha.2024.116132_bib3","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41571-021-00509-w","article-title":"Towards precision medicine for AML","volume":"18","author":"Dohner","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.biopha.2024.116132_bib4","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.leukres.2015.06.017","article-title":"Bone marrow niche in the myelodysplastic syndromes","volume":"39","author":"Cogle","year":"2015","journal-title":"Leuk. Res"},{"issue":"11","key":"10.1016\/j.biopha.2024.116132_bib5","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.27513","article-title":"Acute promyelocytic leukemia (APL): a review of the literature","volume":"11","author":"Jimenez","year":"2020","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2024.116132_bib6","article-title":"Generalist in allogeneic hematopoietic stem cell transplantation for MDS or AML: Epigenetic therapy","volume":"13","author":"Yang","year":"2022","journal-title":"Front Immunol."},{"issue":"6","key":"10.1016\/j.biopha.2024.116132_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23063304","article-title":"Increasing role of targeted immunotherapies in the treatment of AML","volume":"23","author":"Greiner","year":"2022","journal-title":"Int J. Mol. Sci."},{"issue":"19","key":"10.1016\/j.biopha.2024.116132_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/ijms221910232","article-title":"Molecular targeted therapy and immunotherapy for myelodysplastic syndrome","volume":"22","author":"Lee","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.biopha.2024.116132_bib9","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.blre.2017.03.004","article-title":"The bone marrow microenvironment - Home of the leukemic blasts","volume":"31","author":"Shafat","year":"2017","journal-title":"Blood Rev."},{"key":"10.1016\/j.biopha.2024.116132_bib10","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/bs.acr.2018.12.005","article-title":"Exploiting epigenetically mediated changes: acute myeloid leukemia, leukemia stem cells and the bone marrow microenvironment","volume":"141","author":"Kogan","year":"2019","journal-title":"Adv. Cancer Res"},{"key":"10.1016\/j.biopha.2024.116132_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2022.100932","article-title":"Endothelial cells: major players in acute myeloid leukaemia","volume":"54","author":"Fodil","year":"2022","journal-title":"Blood Rev."},{"key":"10.1016\/j.biopha.2024.116132_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.764698","article-title":"The bone marrow microenvironment mechanisms in acute myeloid leukemia","volume":"9","author":"Pimenta","year":"2021","journal-title":"Front Cell Dev. Biol."},{"issue":"2","key":"10.1016\/j.biopha.2024.116132_bib13","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1182\/blood-2011-04-348151","article-title":"Functional inhibition of osteoblastic cells in an in vivo mouse model of myeloid leukemia","volume":"119","author":"Frisch","year":"2012","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.biopha.2024.116132_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22126526","article-title":"Tumor-associated macrophages as multifaceted regulators of breast tumor growth","volume":"22","author":"Munir","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2024.116132_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.874589","article-title":"Tumor-associated macrophages regulate PD-1\/PD-L1 immunosuppression","volume":"13","author":"Pu","year":"2022","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.biopha.2024.116132_bib16","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s00018-017-2686-7","article-title":"CD4 and CD8 T lymphocyte interplay in controlling tumor growth","volume":"75","author":"Ostroumov","year":"2018","journal-title":"Cell Mol. Life Sci."},{"issue":"7","key":"10.1016\/j.biopha.2024.116132_bib17","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1158\/1078-0432.CCR-19-3003","article-title":"Characterization of immune dysfunction and identification of prognostic immune-related risk factors in acute myeloid leukemia","volume":"26","author":"Tang","year":"2020","journal-title":"Clin. Cancer Res"},{"issue":"5","key":"10.1016\/j.biopha.2024.116132_bib18","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/s41568-020-0245-2","article-title":"Bone marrow niches in haematological malignancies","volume":"20","author":"Mendez-Ferrer","year":"2020","journal-title":"Nat. Rev. Cancer"},{"issue":"4","key":"10.1016\/j.biopha.2024.116132_bib19","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrclinonc.2017.197","article-title":"The bone-marrow niche in MDS and MGUS: implications for AML and MM","volume":"15","author":"Ghobrial","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.biopha.2024.116132_bib20","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1182\/blood-2016-09-670224","article-title":"Myeloid malignancies and the microenvironment","volume":"129","author":"Korn","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2024.116132_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.924567","article-title":"Acute myeloid leukaemia drives metabolic changes in the bone marrow niche","volume":"12","author":"Maynard","year":"2022","journal-title":"Front Oncol."},{"issue":"7487","key":"10.1016\/j.biopha.2024.116132_bib22","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/nature12883","article-title":"Leukaemogenesis induced by an activating beta-catenin mutation in osteoblasts","volume":"506","author":"Kode","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2024.116132_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.811144","article-title":"Tumor microenvironment in acute myeloid leukemia: adjusting niches","volume":"13","author":"Menter","year":"2022","journal-title":"Front Immunol."},{"issue":"6","key":"10.1016\/j.biopha.2024.116132_bib24","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1056\/NEJMoa1611604","article-title":"Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation","volume":"376","author":"Lindsley","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.biopha.2024.116132_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.stem.2019.06.007","article-title":"Remodeling of bone marrow hematopoietic stem cell niches promotes myeloid cell expansion during premature or physiological aging","volume":"25","author":"Ho","year":"2019","journal-title":"Cell Stem Cell"},{"issue":"3","key":"10.1016\/j.biopha.2024.116132_bib26","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/leu.2017.259","article-title":"Acute myeloid leukemia transforms the bone marrow niche into a leukemia-permissive microenvironment through exosome secretion","volume":"32","author":"Kumar","year":"2018","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.biopha.2024.116132_bib27","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/s41423-020-00574-8","article-title":"Single-cell profiling reveals the trajectories of natural killer cell differentiation in bone marrow and a stress signature induced by acute myeloid leukemia","volume":"18","author":"Crinier","year":"2021","journal-title":"Cell Mol. Immunol."},{"issue":"3","key":"10.1016\/j.biopha.2024.116132_bib28","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/s41375-022-01798-5","article-title":"Microenvironmental CXCL12 deletion enhances Flt3-ITD acute myeloid leukemia stem cell response to therapy by reducing p38 MAPK signaling","volume":"37","author":"Anderson","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.biopha.2024.116132_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.00697","article-title":"CAR T cells for acute myeloid leukemia: state of the art and future directions","volume":"10","author":"Mardiana","year":"2020","journal-title":"Front Oncol."},{"key":"10.1016\/j.biopha.2024.116132_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.775128","article-title":"Leukemic stem cells: from leukemic niche biology to treatment opportunities","volume":"12","author":"Marchand","year":"2021","journal-title":"Front Immunol."},{"issue":"2","key":"10.1016\/j.biopha.2024.116132_bib31","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3324\/haematol.2022.280800","article-title":"Leukemic stem cells and therapy resistance in acute myeloid leukemia","volume":"108","author":"Stelmach","year":"2023","journal-title":"Haematologica"},{"issue":"6859","key":"10.1016\/j.biopha.2024.116132_bib32","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/35102167","article-title":"Stem cells, cancer, and cancer stem cells","volume":"414","author":"Reya","year":"2001","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.biopha.2024.116132_bib33","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s10555-022-10069-9","article-title":"Mesenchymal stromal cell senescence in haematological malignancies","volume":"42","author":"Plakhova","year":"2023","journal-title":"Cancer Metastas-.-. Rev."},{"issue":"1","key":"10.1016\/j.biopha.2024.116132_bib34","doi-asserted-by":"crossref","DOI":"10.1186\/s13287-018-1013-z","article-title":"Mesenchymal stromal cells from myelodysplastic and acute myeloid leukemia patients display in vitro reduced proliferative potential and similar capacity to support leukemia cell survival","volume":"9","author":"Corradi","year":"2018","journal-title":"Stem Cell Res Ther."},{"issue":"22","key":"10.1016\/j.biopha.2024.116132_bib35","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1182\/blood-2016-08-736454","article-title":"Inhibition of WNT signaling in the bone marrow niche prevents the development of MDS in the Apc(del\/+) MDS mouse model.","volume":"129","author":"Stoddart","year":"2017","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.biopha.2024.116132_bib36","doi-asserted-by":"crossref","DOI":"10.3390\/cells10123376","article-title":"The role of T cell immunotherapy in acute myeloid leukemia","volume":"10","author":"Hao","year":"2021","journal-title":"Cells"},{"issue":"9","key":"10.1016\/j.biopha.2024.116132_bib37","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1002\/cncr.31896","article-title":"The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia","volume":"125","author":"Williams","year":"2019","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2024.116132_bib38","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00262-013-1490-y","article-title":"Regulatory T cell subsets in human cancer: are they regulating for or against tumor progression?","volume":"63","author":"Whiteside","year":"2014","journal-title":"Cancer Immunol., Immunother.: CII"},{"issue":"5","key":"10.1016\/j.biopha.2024.116132_bib39","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.3109\/10428194.2014.953150","article-title":"Expression of indoleamine 2,3-dioxygenase in leukemic cells indicates an unfavorable prognosis in acute myeloid leukemia patients with intermediate-risk cytogenetics","volume":"56","author":"Fukuno","year":"2015","journal-title":"Leuk. Lymphoma"},{"issue":"1","key":"10.1016\/j.biopha.2024.116132_bib40","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-021-01062-w","article-title":"Emerging agents and regimens for AML","volume":"14","author":"Liu","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"10","key":"10.1016\/j.biopha.2024.116132_bib41","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/s41577-019-0191-y","article-title":"Mucosal-associated invariant T cells and disease","volume":"19","author":"Toubal","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.biopha.2024.116132_bib42","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.656218","article-title":"Immunotherapy in acute myeloid leukemia: where we stand","volume":"11","author":"Isidori","year":"2021","journal-title":"Front Oncol."},{"key":"10.1016\/j.biopha.2024.116132_bib43","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/4868417","article-title":"Effect of natural compounds on NK cell activation","volume":"2018","author":"Grudzien","year":"2018","journal-title":"J. Immunol. Res."},{"issue":"15","key":"10.1016\/j.biopha.2024.116132_bib44","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1182\/blood-2009-06-227934","article-title":"CD137 ligand mediates opposite effects in human and mouse NK cells and impairs NK-cell reactivity against human acute myeloid leukemia cells","volume":"115","author":"Baessler","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.biopha.2024.116132_bib45","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1146\/annurev.immunol.23.021704.115526","article-title":"NK cell recognition","volume":"23","author":"Lanier","year":"2005","journal-title":"Annu Rev. Immunol."},{"issue":"7","key":"10.1016\/j.biopha.2024.116132_bib46","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13071568","article-title":"Realizing innate potential: CAR-NK cell therapies for acute myeloid leukemia","volume":"13","author":"Gurney","year":"2021","journal-title":"Cancers"},{"issue":"12","key":"10.1016\/j.biopha.2024.116132_bib47","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/nrd.2018.169","article-title":"Targeting macrophages: therapeutic approaches in cancer","volume":"17","author":"Cassetta","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"issue":"7","key":"10.1016\/j.biopha.2024.116132_bib48","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","article-title":"Tumour-associated macrophages as treatment targets in oncology","volume":"14","author":"Mantovani","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.biopha.2024.116132_bib49","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1002\/cac2.12345","article-title":"Tumor-associated macrophages in liver cancer: from mechanisms to therapy","volume":"42","author":"Cheng","year":"2022","journal-title":"Cancer Commun. (Lond. )"},{"issue":"3","key":"10.1016\/j.biopha.2024.116132_bib50","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.7150\/thno.51777","article-title":"Metabolic regulatory crosstalk between tumor microenvironment and tumor-associated macrophages","volume":"11","author":"Chen","year":"2021","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.biopha.2024.116132_bib51","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-023-01723-z","article-title":"CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances","volume":"22","author":"Maalej","year":"2023","journal-title":"Mol. Cancer"},{"issue":"6","key":"10.1016\/j.biopha.2024.116132_bib52","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000572","article-title":"Treatment for relapsed\/refractory acute myeloid leukemia","volume":"5","author":"Thol","year":"2021","journal-title":"Hemasphere"},{"issue":"4","key":"10.1016\/j.biopha.2024.116132_bib53","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1172\/JCI129204","article-title":"Immune escape and immunotherapy of acute myeloid leukemia","volume":"130","author":"Vago","year":"2020","journal-title":"J. Clin. Invest"},{"issue":"12","key":"10.1016\/j.biopha.2024.116132_bib54","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14122994","article-title":"Vaccination therapy for acute myeloid leukemia: where do we stand?","volume":"14","author":"Barbullushi","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2024.116132_bib55","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3389\/fimmu.2015.00036","article-title":"Review of the results of WT1 peptide vaccination strategies for myelodysplastic syndromes and acute myeloid leukemia from nine different studies","volume":"6","author":"Di Stasi","year":"2015","journal-title":"Front Immunol."},{"issue":"2","key":"10.1016\/j.biopha.2024.116132_bib56","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/BF02981935","article-title":"Wilms' tumor gene WT1: its oncogenic function and clinical application","volume":"73","author":"Sugiyama","year":"2001","journal-title":"Int J. Hematol."},{"issue":"3","key":"10.1016\/j.biopha.2024.116132_bib57","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1182\/bloodadvances.2017014175","article-title":"Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia","volume":"2","author":"Maslak","year":"2018","journal-title":"Blood Adv."},{"issue":"6","key":"10.1016\/j.biopha.2024.116132_bib58","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1080\/13543784.2021.1928635","article-title":"Galinpepimut-S (GPS): an investigational agent for the treatment of acute myeloid leukemia","volume":"30","author":"Jain","year":"2021","journal-title":"Expert Opin. Invest. Drugs"},{"issue":"7","key":"10.1016\/j.biopha.2024.116132_bib59","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.3324\/haematol.2009.014704","article-title":"High-dose RHAMM-R3 peptide vaccination for patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma","volume":"95","author":"Greiner","year":"2010","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.biopha.2024.116132_bib60","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s00262-021-02993-6","article-title":"Epigenetic therapy in combination with a multi-epitope cancer vaccine targeting shared tumor antigens for high-risk myelodysplastic syndrome - a phase I clinical trial","volume":"71","author":"Holmberg-Thyd\u00e9n","year":"2022","journal-title":"Cancer Immunol., Immunother.: CII"},{"issue":"5","key":"10.1016\/j.biopha.2024.116132_bib61","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8050579","article-title":"Dendritic cell-based immunotherapy of acute myeloid leukemia","volume":"8","author":"Van Acker","year":"2019","journal-title":"J. Clin. Med"},{"issue":"1","key":"10.1016\/j.biopha.2024.116132_bib62","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41577-019-0210-z","article-title":"Dendritic cells in cancer immunology and immunotherapy","volume":"20","author":"Wculek","year":"2020","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2024.116132_bib63","doi-asserted-by":"crossref","DOI":"10.1186\/s40164-022-00257-2","article-title":"Research progress on dendritic cell vaccines in cancer immunotherapy","volume":"11","author":"Yu","year":"2022","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.biopha.2024.116132_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2020.108467","article-title":"Potential of immunotherapies in the mediation of antileukemic responses for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) - With a focus on Dendritic cells of leukemic origin (DCleu)","volume":"217","author":"Ansprenger","year":"2020","journal-title":"Clin. Immunol."},{"issue":"4","key":"10.1016\/j.biopha.2024.116132_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.imbio.2022.152237","article-title":"Leukemia derived dendritic cell (DC(leu)) mediated immune response goes along with reduced (leukemia-specific) regulatory T-cells","volume":"227","author":"Pepeldjiyska","year":"2022","journal-title":"Immunobiology"},{"key":"10.1016\/j.biopha.2024.116132_bib66","doi-asserted-by":"crossref","first-page":"496","DOI":"10.3389\/fimmu.2013.00496","article-title":"Dendritic cell-based immunotherapy for myeloid leukemias","volume":"4","author":"Schurch","year":"2013","journal-title":"Front Immunol."},{"issue":"10","key":"10.1016\/j.biopha.2024.116132_bib67","doi-asserted-by":"crossref","first-page":"3511","DOI":"10.1080\/21645515.2021.1943991","article-title":"A phase I\/II feasibility vaccine study by autologous leukemic apoptotic corpse-pulsed dendritic cells for elderly AML patients","volume":"17","author":"Chevallier","year":"2021","journal-title":"Hum. Vaccin Immunother."},{"issue":"2","key":"10.1016\/j.biopha.2024.116132_bib68","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/jca.10080","article-title":"Immunotherapy using autologous monocyte-derived dendritic cells pulsed with leukemic cell lysates for acute myeloid leukemia relapse after autologous peripheral blood stem cell transplantation","volume":"19","author":"Lee","year":"2004","journal-title":"J. Clin. Apher."},{"issue":"22","key":"10.1016\/j.biopha.2024.116132_bib69","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.764.764","article-title":"Induction of antigen-specific T-cell responses through dendritic cell vaccination in AML: results of a phase I\/II trial and ex vivo enhancement by checkpoint blockade","volume":"128","author":"Lichtenegger","year":"2016","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.biopha.2024.116132_bib70","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood-2017-04-780155","article-title":"Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia","volume":"130","author":"Anguille","year":"2017","journal-title":"Blood"},{"issue":"368","key":"10.1016\/j.biopha.2024.116132_bib71","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aag1298","article-title":"Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions","volume":"8","author":"Rosenblatt","year":"2016","journal-title":"Sci. Transl. Med"},{"issue":"2","key":"10.1016\/j.biopha.2024.116132_bib72","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1097\/MOH.0000000000000637","article-title":"Maintenance therapy for acute myeloid leukemia: sustaining the pursuit for sustained remission","volume":"28","author":"Shallis","year":"2021","journal-title":"Curr. Opin. Hematol."},{"issue":"10","key":"10.1016\/j.biopha.2024.116132_bib73","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1007\/s00262-018-2198-9","article-title":"A novel allogeneic off-the-shelf dendritic cell vaccine for post-remission treatment of elderly patients with acute myeloid leukemia","volume":"67","author":"van de Loosdrecht","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"issue":"9","key":"10.1016\/j.biopha.2024.116132_bib74","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1038\/s41375-023-01980-3","article-title":"WT1 and PRAME RNA-loaded dendritic cell vaccine as maintenance therapy in de novo AML after intensive induction chemotherapy","volume":"37","author":"Fl\u00f8isand","year":"2023","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.biopha.2024.116132_bib75","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/bjh.16358","article-title":"Checkpoint inhibitors in AML: are we there yet?","volume":"188","author":"Ghosh","year":"2020","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.biopha.2024.116132_bib76","doi-asserted-by":"crossref","DOI":"10.1186\/s12935-023-02902-0","article-title":"Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired","volume":"23","author":"Marei","year":"2023","journal-title":"Cancer Cell Int"},{"issue":"14","key":"10.1016\/j.biopha.2024.116132_bib77","doi-asserted-by":"crossref","DOI":"10.3390\/cells11142249","article-title":"Immune checkpoint inhibition in acute myeloid leukemia and myelodysplastic syndromes","volume":"11","author":"Abaza","year":"2022","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.biopha.2024.116132_bib78","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8020236","article-title":"Targeting immune signaling checkpoints in acute myeloid leukemia","volume":"8","author":"Giannopoulos","year":"2019","journal-title":"J. Clin. Med"},{"issue":"1","key":"10.1016\/j.biopha.2024.116132_bib79","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-019-1259-z","article-title":"Combination of CTLA-4 and PD-1 blockers for treatment of cancer","volume":"38","author":"Rotte","year":"2019","journal-title":"J. Exp. Clin. Cancer Res"},{"issue":"16","key":"10.1016\/j.biopha.2024.116132_bib80","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.biopha.2024.116132_bib81","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1056\/NEJMoa1601202","article-title":"Ipilimumab for patients with relapse after allogeneic transplantation","volume":"375","author":"Davids","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2024.116132_bib82","unstructured":"Garcia J.S., Flamand Y., Penter L., Keng M., Tomlinson B., Mendez L.M., et al. Ipilimumab plus decitabine for patients with MDS or AML in post-transplant or transplant na\u00efve settings. Blood 2022."},{"issue":"2","key":"10.1016\/j.biopha.2024.116132_bib83","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1056\/NEJMoa1601202","article-title":"Ipilimumab for patients with relapse after allogeneic transplantation","volume":"375","author":"Davids","year":"2016","journal-title":"N. Engl. J. Med"},{"issue":"3","key":"10.1016\/j.biopha.2024.116132_bib84","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1007\/s10147-016-0959-z","article-title":"PD-1\/PD-L1 blockade in cancer treatment: perspectives and issues","volume":"21","author":"Hamanishi","year":"2016","journal-title":"Int J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2024.116132_bib85","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2019.00609","article-title":"A review of efficacy and safety of checkpoint inhibitor for the treatment of acute myeloid leukemia","volume":"10","author":"Liao","year":"2019","journal-title":"Front Pharm."},{"issue":"1","key":"10.1016\/j.biopha.2024.116132_bib86","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s13045-022-01328-x","article-title":"Targeting macrophages in hematological malignancies: recent advances and future directions","volume":"15","author":"Li","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2024.116132_bib87","doi-asserted-by":"crossref","DOI":"10.1186\/s40164-022-00263-4","article-title":"Targeting PD-1\/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia","volume":"11","author":"Yang","year":"2022","journal-title":"Exp. Hematol. Oncol."},{"issue":"3","key":"10.1016\/j.biopha.2024.116132_bib88","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.molcel.2019.09.030","article-title":"Mechanisms controlling PD-L1 expression in cancer","volume":"76","author":"Cha","year":"2019","journal-title":"Mol. Cell"},{"issue":"4","key":"10.1016\/j.biopha.2024.116132_bib89","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41591-019-0400-z","article-title":"Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation","volume":"25","author":"Toffalori","year":"2019","journal-title":"Nat. Med."},{"issue":"12","key":"10.1016\/j.biopha.2024.116132_bib90","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1111\/jcmm.17390","article-title":"Expression of PD-L1 on regulatory B cells in patients with acute myeloid leukaemia and its effect on prognosis","volume":"26","author":"Shi","year":"2022","journal-title":"J. Cell Mol. Med"},{"issue":"4","key":"10.1016\/j.biopha.2024.116132_bib91","article-title":"Is There a Place for PD-1-PD-L Blockade in Acute Myeloid Leukemia?","volume":"14","author":"Jimbu","year":"2021","journal-title":"Pharm. (Basel)"},{"issue":"2","key":"10.1016\/j.biopha.2024.116132_bib92","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1177\/1758834014567469","article-title":"Nivolumab in melanoma: latest evidence and clinical potential","volume":"7","author":"Johnson","year":"2015","journal-title":"Ther. Adv. Med Oncol."},{"issue":"3","key":"10.1016\/j.biopha.2024.116132_bib93","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1158\/2159-8290.CD-18-0774","article-title":"Efficacy, safety, and biomarkers of response to azacitidine and nivolumab in relapsed\/refractory acute myeloid leukemia: a nonrandomized, open-label, phase II study","volume":"9","author":"Daver","year":"2019","journal-title":"Cancer Discov."},{"issue":"Supplement_1","key":"10.1016\/j.biopha.2024.116132_bib94","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-131494","article-title":"Azacitidine (AZA) with nivolumab (Nivo), and AZA with Nivo + ipilimumab (Ipi) in relapsed\/refractory acute myeloid leukemia: a non-randomized, prospective, phase 2 study","volume":"134","author":"Daver","year":"2019","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.biopha.2024.116132_bib95","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/cncr.34566","article-title":"Triple combination targeting methyltransferase, BCL-2, and PD-1 facilitates antileukemia responses in acute myeloid leukemia","volume":"129","author":"Zeng","year":"2023","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2024.116132_bib96","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003392","article-title":"Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia","volume":"10","author":"Goswami","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"6","key":"10.1016\/j.biopha.2024.116132_bib97","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1182\/bloodadvances.2022008403","article-title":"Pembrolizumab for the treatment of disease relapse after allogeneic hematopoietic stem cell transplantation","volume":"7","author":"Godfrey","year":"2023","journal-title":"Blood Adv."},{"issue":"12","key":"10.1016\/j.biopha.2024.116132_bib98","article-title":"Safety and efficacy of pembrolizumab prior to allogeneic stem cell transplantation for acute myelogenous leukemia","volume":"27","author":"Tschernia","year":"2021","journal-title":"Transpl. Cell Ther."},{"issue":"7","key":"10.1016\/j.biopha.2024.116132_bib99","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1182\/bloodadvances.2021006138","article-title":"A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML","volume":"6","author":"Zeidan","year":"2022","journal-title":"Blood Adv."},{"issue":"20","key":"10.1016\/j.biopha.2024.116132_bib100","doi-asserted-by":"crossref","first-page":"3761","DOI":"10.1002\/cncr.33690","article-title":"A phase 1b\/2 study of azacitidine with PD-L1 antibody avelumab in relapsed\/refractory acute myeloid leukemia","volume":"127","author":"Saxena","year":"2021","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2024.116132_bib101","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000911","article-title":"Tim-3 finds its place in the cancer immunotherapy landscape","volume":"8","author":"Acharya","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2024.116132_bib102","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-019-0611-3","article-title":"Gal9\/Tim-3 expression level is higher in AML patients who fail chemotherapy","volume":"7","author":"Dama","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"13","key":"10.1016\/j.biopha.2024.116132_bib103","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.1158\/1078-0432.CCR-20-4746","article-title":"Phase I\/Ib clinical trial of sabatolimab, an Anti-TIM-3 antibody, alone and in combination with spartalizumab, an anti-PD-1 antibody, in advanced solid tumors","volume":"27","author":"Curigliano","year":"2021","journal-title":"Clin. Cancer Res"},{"issue":"3","key":"10.1016\/j.biopha.2024.116132_bib104","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.stem.2015.07.011","article-title":"A TIM-3\/Gal-9 autocrine stimulatory loop drives self-renewal of human myeloid leukemia stem cells and leukemic progression","volume":"17","author":"Kikushige","year":"2015","journal-title":"Cell Stem Cell"},{"issue":"Supplement 1","key":"10.1016\/j.biopha.2024.116132_bib105","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-146039","article-title":"Efficacy and safety of sabatolimab (MBG453) in combination with hypomethylating agents (HMAs) in patients (Pts) with very high\/high-risk myelodysplastic syndrome (vHR\/HR-MDS) and acute myeloid leukemia (aml): final analysis from a phase Ib study","volume":"138","author":"Brunner","year":"2021","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.biopha.2024.116132_bib106","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/s41591-019-0356-z","article-title":"Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRP\u03b1 axis and a target for cancer immunotherapy","volume":"25","author":"Logtenberg","year":"2019","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.biopha.2024.116132_bib107","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000905","article-title":"CD47\/SIRP\u03b1 blocking peptide identification and synergistic effect with irradiation for cancer immunotherapy","volume":"8","author":"Wang","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"2","key":"10.1016\/j.biopha.2024.116132_bib108","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.cell.2009.05.045","article-title":"CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells","volume":"138","author":"Majeti","year":"2009","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.biopha.2024.116132_bib109","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1111\/trf.15397","article-title":"The effects of monoclonal anti-CD47 on RBCs, compatibility testing, and transfusion requirements in refractory acute myeloid leukemia","volume":"59","author":"Brierley","year":"2019","journal-title":"Transfusion"},{"issue":"3","key":"10.1016\/j.biopha.2024.116132_bib110","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00277-021-04734-2","article-title":"Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed\/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes","volume":"101","author":"Zeidan","year":"2022","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.biopha.2024.116132_bib111","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.02227","article-title":"Acute myeloid leukemia cells express ICOS ligand to promote the expansion of regulatory T cells","volume":"9","author":"Han","year":"2018","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2024.116132_bib112","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13045-023-01410-y","article-title":"Targeting STAT3-VISTA axis to suppress tumor aggression and burden in acute myeloid leukemia","volume":"16","author":"Mo","year":"2023","journal-title":"J. Hematol. Oncol."},{"issue":"11","key":"10.1016\/j.biopha.2024.116132_bib113","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1182\/blood.2022015522","article-title":"Immune landscape after allo-HSCT: TIGIT- and CD161-expressing CD4 T cells are associated with subsequent leukemia relapse","volume":"140","author":"Gournay","year":"2022","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.biopha.2024.116132_bib114","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1158\/2159-8290.CD-20-0312","article-title":"Multidimensional analyses of donor memory-like NK cells reveal new associations with response after adoptive immunotherapy for leukemia","volume":"10","author":"Berrien-Elliott","year":"2020","journal-title":"Cancer Discov."},{"issue":"8","key":"10.1016\/j.biopha.2024.116132_bib115","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007202","article-title":"NKG2A gene variant predicts outcome of immunotherapy in AML and modulates the repertoire and function of NK cells","volume":"11","author":"Hussein","year":"2023","journal-title":"J. Immunother. Cancer"},{"issue":"7","key":"10.1016\/j.biopha.2024.116132_bib116","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1038\/s41375-021-01253-x","article-title":"T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments","volume":"35","author":"Daver","year":"2021","journal-title":"Leukemia"},{"issue":"18","key":"10.1016\/j.biopha.2024.116132_bib117","doi-asserted-by":"crossref","first-page":"4110","DOI":"10.1200\/JCO.2005.09.133","article-title":"Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia","volume":"23","author":"Feldman","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.biopha.2024.116132_bib118","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2020007732","article-title":"Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia","volume":"137","author":"Uy","year":"2021","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.biopha.2024.116132_bib119","article-title":"Safety and efficacy of pembrolizumab prior to allogeneic stem cell transplantation for acute myelogenous leukemia","volume":"27","author":"Tschernia","year":"2021","journal-title":"Transpl. Cell Ther."},{"issue":"9","key":"10.1016\/j.biopha.2024.116132_bib120","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/s41591-020-0910-8","article-title":"Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents","volume":"26","author":"Riether","year":"2020","journal-title":"Nat. Med"},{"key":"10.1016\/j.biopha.2024.116132_bib121","article-title":"Results from a phase I\/II trial of cusatuzumab combined with azacitidine in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy","volume":"0","author":"Pabst","year":"2023","journal-title":"Haematologica"},{"issue":"16","key":"10.1016\/j.biopha.2024.116132_bib122","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13164113","article-title":"A clinical phase 1B study of the CD3xCD123 bispecific antibody APVO436 in patients with relapsed\/refractory acute myeloid leukemia or myelodysplastic syndrome","volume":"13","author":"Uckun","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2024.116132_bib123","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2021.12.029","article-title":"Targeted inhibitors and antibody immunotherapies: Novel therapies for paediatric leukaemia and lymphoma","volume":"164","author":"Brivio","year":"2022","journal-title":"Eur. J. Cancer"},{"issue":"12","key":"10.1016\/j.biopha.2024.116132_bib124","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1007\/s00262-021-03008-0","article-title":"CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL","volume":"70","author":"Reusing","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"issue":"15_suppl","key":"10.1016\/j.biopha.2024.116132_bib125","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.7508","article-title":"Updated results from phase I dose-escalation study of AMG 330, a bispecific T-cell engager molecule, in patients with relapsed\/refractory acute myeloid leukemia (R\/R AML)","volume":"38","author":"Ravandi","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"Supplement 1","key":"10.1016\/j.biopha.2024.116132_bib126","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1182\/blood-2020-134746","article-title":"Complete responses in relapsed\/refractory acute Myeloid Leukemia (AML) patients on a weekly dosing schedule of vibecotamab (XmAb14045), a CD123 x CD3 T cell-engaging bispecific antibody; initial results of a phase 1 study","volume":"136","author":"Ravandi","year":"2020","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.biopha.2024.116132_bib127","doi-asserted-by":"crossref","first-page":"4854","DOI":"10.1182\/blood-2013-01-466706","article-title":"A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia","volume":"121","author":"Petersdorf","year":"2013","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.biopha.2024.116132_bib128","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1080\/17512433.2018.1478725","article-title":"Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia","volume":"11","author":"Baron","year":"2018","journal-title":"Expert Rev. Clin. Pharm."},{"key":"10.1016\/j.biopha.2024.116132_bib129","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102409","article-title":"Emerging antibody-based therapies for the treatment of acute myeloid leukemia","volume":"108","author":"Angenendt","year":"2022","journal-title":"Cancer Treat. Rev."},{"issue":"9","key":"10.1016\/j.biopha.2024.116132_bib130","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S1470-2045(14)70281-5","article-title":"Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials","volume":"15","author":"Hills","year":"2014","journal-title":"Lancet Oncol."},{"issue":"12","key":"10.1016\/j.biopha.2024.116132_bib131","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14122934","article-title":"Phase 1\/2 trial of CLAG-M with dose-escalated mitoxantrone in combination with fractionated-dose gemtuzumab ozogamicin for newly diagnosed acute myeloid leukemia and other high-grade myeloid neoplasms","volume":"14","author":"Godwin","year":"2022","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.biopha.2024.116132_bib132","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3324\/haematol.2012.071092","article-title":"Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195\/rGEL), in patients with advanced myeloid malignancies","volume":"98","author":"Borthakur","year":"2013","journal-title":"Haematologica"},{"issue":"18","key":"10.1016\/j.biopha.2024.116132_bib133","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13184566","article-title":"Therapeutic targeting of acute myeloid leukemia by gemtuzumab ozogamicin","volume":"13","author":"Gottardi","year":"2021","journal-title":"Cancers"},{"issue":"26","key":"10.1016\/j.biopha.2024.116132_bib134","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1182\/blood.2020005998","article-title":"Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial","volume":"136","author":"Kapp-Schwoerer","year":"2020","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.biopha.2024.116132_bib135","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1182\/bloodadvances.2018017517","article-title":"A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells","volume":"2","author":"Kovtun","year":"2018","journal-title":"Blood Adv."},{"issue":"Supplement_1","key":"10.1016\/j.biopha.2024.116132_bib136","article-title":"Clinical profile of IMGN632, a novel cd123-targeting antibody-drug conjugate (ADC), in patients with relapsed\/refractory (R\/R) acute Myeloid Leukemia (AML) or blastic plasmacytoid dendritic cell neoplasm (BPDCN)","volume":"134","author":"Daver","year":"2019","journal-title":"Blood"},{"issue":"224","key":"10.1016\/j.biopha.2024.116132_bib137","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci. Transl. Med"},{"issue":"2","key":"10.1016\/j.biopha.2024.116132_bib138","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/13543784.2022.2032642","article-title":"Prospect of CAR T-cell therapy in acute myeloid leukemia","volume":"31","author":"Badar","year":"2022","journal-title":"Expert Opin. Invest. Drugs"},{"issue":"1","key":"10.1016\/j.biopha.2024.116132_bib139","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/mt.2014.164","article-title":"Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia","volume":"23","author":"Wang","year":"2015","journal-title":"Mol. Ther."},{"issue":"Supplement 1","key":"10.1016\/j.biopha.2024.116132_bib140","article-title":"Remissions of acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm following treatment with CD123-specific CAR T cells: a first-in-human clinical trial","volume":"130","author":"Budde","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.biopha.2024.116132_bib141","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13045-022-01308-1","article-title":"First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed\/refractory acute myeloid leukemia","volume":"15","author":"Jin","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2024.116132_bib142","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12943-022-01541-9","article-title":"A novel approach for relapsed\/refractory FLT3mut+ acute myeloid leukaemia: synergistic effect of the combination of bispecific FLT3scFv\/NKG2D-CAR T cells and gilteritinib","volume":"21","author":"Li","year":"2022","journal-title":"Mol. Cancer"},{"issue":"9","key":"10.1016\/j.biopha.2024.116132_bib143","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1043","article-title":"CD44v6 chimeric antigen receptor T cell specificity towards AML with FLT3 or DNMT3A mutations","volume":"12","author":"Tang","year":"2022","journal-title":"Clin. Transl. Med"},{"issue":"4","key":"10.1016\/j.biopha.2024.116132_bib144","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1182\/blood.2020008221","article-title":"CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity","volume":"138","author":"Sauer","year":"2021","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.biopha.2024.116132_bib145","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-153927","article-title":"Developing a safer anti-CD44v6 chimeric antigen receptor T cell against hematological cancers by mitigating on-target off-tumor toxicity","volume":"138","author":"Awuah","year":"2021","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.biopha.2024.116132_bib146","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1182\/blood-2013-04-493361","article-title":"CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma","volume":"122","author":"Casucci","year":"2013","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.biopha.2024.116132_bib147","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s41576-021-00329-9","article-title":"Genetic engineering of T cells for immunotherapy","volume":"22","author":"Ellis","year":"2021","journal-title":"Nat. Rev. Genet"},{"issue":"3","key":"10.1016\/j.biopha.2024.116132_bib148","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/PPO.0000000000000378","article-title":"T-cell receptor-based immunotherapy for hematologic malignancies","volume":"25","author":"Biernacki","year":"2019","journal-title":"Cancer J."},{"issue":"7","key":"10.1016\/j.biopha.2024.116132_bib149","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1038\/s41591-019-0472-9","article-title":"T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant","volume":"25","author":"Chapuis","year":"2019","journal-title":"Nat. Med"},{"issue":"1","key":"10.1016\/j.biopha.2024.116132_bib150","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15010168","article-title":"Tailored functionalized protein nanocarriers for cancer therapy: recent developments and prospects","volume":"15","author":"Abdelhamid","year":"2023","journal-title":"Pharmaceutics"},{"issue":"5","key":"10.1016\/j.biopha.2024.116132_bib151","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.jaad.2020.03.132","article-title":"Immune checkpoint inhibitor-related dermatologic adverse events","volume":"83","author":"Geisler","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"issue":"1","key":"10.1016\/j.biopha.2024.116132_bib152","article-title":"Immunotherapy in hematologic malignancies: achievements, challenges and future prospects","volume":"8","author":"Tang","year":"2023","journal-title":"Signal Transduct. Target Ther."},{"issue":"4","key":"10.1016\/j.biopha.2024.116132_bib153","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrd3003","article-title":"The safety and side effects of monoclonal antibodies","volume":"9","author":"Hansel","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.biopha.2024.116132_bib154","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/cncr.34507","article-title":"Treatment-related adverse events of antibody-drug conjugates in clinical trials: a systematic review and meta-analysis","volume":"129","author":"Zhu","year":"2023","journal-title":"Cancer"},{"issue":"41","key":"10.1016\/j.biopha.2024.116132_bib155","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_320085","article-title":"CAR T-cell therapy in hematologic malignancies: clinical role, toxicity, and unanswered questions","author":"Gill","year":"2021","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"issue":"5","key":"10.1016\/j.biopha.2024.116132_bib156","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jaci.2020.07.025","article-title":"Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies","volume":"146","author":"Freyer","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"issue":"2","key":"10.1016\/j.biopha.2024.116132_bib157","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat. Rev. Immunol."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224000131?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224000131?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:53:51Z","timestamp":1792097631000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332224000131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":157,"alternative-id":["S0753332224000131"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2024.116132","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapies of acute myeloid leukemia: Rationale, clinical evidence and perspective","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2024.116132","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"116132"}}